Finasteride
- ₹6000 - ₹19149.43
- Product name: Finasteride
- CAS: 98319-26-7
- MF: C23H36N2O2
- MW: 372.54
- EINECS:620-534-3
- MDL Number:MFCD00869737
- Synonyms:(5alpha,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide ;17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one ;4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5-alpha,17-be ;4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta ;l-652,931 ;mk-0906 ;n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide ;(5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
4 prices
Selected condition:
Brand
- TCI Chemicals (India)
- Sigma-Aldrich(India)
Package
- 100MG
- 200MG
- 1G
- ManufacturerTCI Chemicals (India)
- Product numberF0675
- Product descriptionFinasteride min. 98.0 %
- Packaging200MG
- Price₹6000
- Updated2022-05-26
- Buy
- ManufacturerTCI Chemicals (India)
- Product numberF0675
- Product descriptionFinasteride min. 98.0 %
- Packaging1G
- Price₹14100
- Updated2022-05-26
- Buy
- ManufacturerSigma-Aldrich(India)
- Product number34202
- Product descriptionFinasteride VETRANAL?, analytical standard
- Packaging100MG
- Price₹19149.43
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberF1293
- Product descriptionFinasteride ≥98% (HPLC), powder
- Packaging100MG
- Price₹11745.13
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
TCI Chemicals (India) | F0675 | Finasteride min. 98.0 % | 200MG | ₹6000 | 2022-05-26 | Buy |
TCI Chemicals (India) | F0675 | Finasteride min. 98.0 % | 1G | ₹14100 | 2022-05-26 | Buy |
Sigma-Aldrich(India) | 34202 | Finasteride VETRANAL?, analytical standard | 100MG | ₹19149.43 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | F1293 | Finasteride ≥98% (HPLC), powder | 100MG | ₹11745.13 | 2022-06-14 | Buy |
Properties
Melting point :253 °C
alpha :405 -59° (c = 1 in methanol)
Boiling point :576.6±50.0 °C(Predicted)
Density :1.065±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :DMSO: 32 mg/mL, soluble
form :solid
pka :14.17±0.70(Predicted)
color :white to beige
Water Solubility :insoluble
Merck :14,4082
BCS Class :1
InChIKey :DBEPLOCGEIEOCV-WSBQPABSSA-N
LogP :3.030
CAS DataBase Reference :98319-26-7(CAS DataBase Reference)
EPA Substance Registry System :1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (98319-26-7)
alpha :405 -59° (c = 1 in methanol)
Boiling point :576.6±50.0 °C(Predicted)
Density :1.065±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :DMSO: 32 mg/mL, soluble
form :solid
pka :14.17±0.70(Predicted)
color :white to beige
Water Solubility :insoluble
Merck :14,4082
BCS Class :1
InChIKey :DBEPLOCGEIEOCV-WSBQPABSSA-N
LogP :3.030
CAS DataBase Reference :98319-26-7(CAS DataBase Reference)
EPA Substance Registry System :1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (98319-26-7)
Safety Information
Symbol(GHS): | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||
Hazard statements: |
|
||||||||||||||
Precautionary statements: |
|
Description
5α-Reductase catalyzes the NADPH-dependent reduction of Δ4,5 double bonds in several steroid substrates, including testosterone, which is converted to dihydrotestosterone, the primary mediator of prostate growth. The 5α-reductase enzymes responsible for the reduction of testosterone to dihydrotestosterone exists as two forms: type I, which occurs in the skin, liver, and ventral prostate and type II, which is expressed in ventral prostate, epididymis, and other reproductive tissues. Finasteride is a 4-azasteroid analog of testosterone that competitively blocks type II 5α-reductase activity (IC50 = 4.2 nM) with 100-fold greater affinity than for the type I enzyme. It has been used in the treatment of benign prostatic hyperplasia, decreasing human prostatic dihydrotestosterone levels by 70-90% and reducing prostatic size. However, at 10 μM finasteride has also been shown to induce the expression of Nrf2 and HO-1 proteins in androgen refractory prostrate PC-3 cells, which has been implicated in increased high-grade prostate tumor formation. Also, at 0.1 μM finasteride can inhibit testosterone-induced type I procollagen and TGF-β1 expression in human scalp dermal fibroblasts in a model of androgenic alopecia.Related product price
- N,N-Dimethylformamide
₹480-928440 - Methyl acrylate
₹693-29790.4 - Basic Violet 1
₹108-19269.6